Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 3,262 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo first Clear all

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: NNC9204-0530, liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 163 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Maternal Behavior, Maternal Addiction
Interventions: Oxytocin, Placebos, Functional MRI scanning; Drug · Procedure
Lead sponsor: Lane Strathearn, MBBS PhD; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: New Haven, Connecticut • Iowa City, Iowa

Conditions: Orthostatic Hypotension
Interventions: Droxidopa, Pyridostigmine, Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Recurrent Respiratory Papillomatosis
Interventions: celebrex (celecoxib), placebo; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 2 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • Iowa City, Iowa + 4 more

Conditions: Non-small Cell Lung Cancer
Interventions: REGN2810, REGN2810/chemo/ipi, Chemotherapy, Placebo; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 789 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 9
States / cities: Rancho Mirage, California • Riverside, California • Whittier, California + 6 more

Conditions: Moderate to Severe Plaque-type Psoriasis
Interventions: Secukinumab (AIN457), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 28 more

Conditions: Asthma
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 75
States / cities: Cullman, Alabama • Sheffield, Alabama • Chandler, Arizona + 66 more

Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Interventions: AVP-786, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 111
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 78 more

Conditions: Lung Cancer
Interventions: Minocycline, Placebo, Questionnaires; Drug · Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Depression
Interventions: Venlafaxine XR, Placebo, JNJ26489112; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 14
States / cities: Arcadia, California • Escondido, California • San Diego, California + 11 more

Conditions: Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, Lobular Carcinoma, Fatigue Related to Cancer Treatment
Interventions: Naltrexone, Sugar Pill; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Bunion, Post-operative Pain
Interventions: Local anesthetic injection of CPL-01, Naropin, 0.5% Injectable Solution, Placebo, Morphine rescue medication, Acetaminophen rescue medication, Oxycodone rescue medication, Bunionectomy; Drug · Procedure
Lead sponsor: Cali Pharmaceuticals LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 616 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Eosinophilic Gastritis, Eosinophilic Duodenitis
Interventions: lirentelimab (AK002), Placebo; Drug · Other
Lead sponsor: Allakos Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 60
States / cities: Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 54 more

Conditions: Post-Amputation Phantom Limb Pain
Interventions: Cryoneurolysis, Sham Comparator; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: Palo Alto, California • San Diego, California • Gainesville, Florida + 2 more

Conditions: Obesity
Interventions: Oral Glucose Tolerance Test (OGTT), Human Ghrelin, Saline; Procedure · Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy Volunteers
Interventions: FTX-101, Placebo; Drug
Lead sponsor: Find Therapeutics; Industry
Eligibility: 18 Years to 59 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: San Diego, La Jolla, California • Gainesville, Florida

Conditions: Small Cell Lung Cancer (SCLC)
Interventions: Pembrolizumab, Normal saline solution, Carboplatin, Cisplatin, Etoposide; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 27
States / cities: Miami, Florida • Chicago, Illinois • Evanston, Illinois + 21 more

Conditions: Healthy Participants
Interventions: Ad35.RSV.FA2, Ad26.RSV.FA2, Placebo; Biological · Drug
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hearing Loss
Interventions: Attention to Variability (ATV), Placebo; Behavioral · Other
Lead sponsor: Harvard University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Arthritis, Rheumatoid
Interventions: CP-690,550, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 36
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 29 more

Conditions: Congenital Heart Disease, Disorder of Fetus or Newborn
Interventions: Methylprednisolone, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: Up to 30 Days
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia • Charleston, South Carolina

Conditions: Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
Interventions: Rezafungin for Injection, Posaconazole, Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Intravenous Placebo, Oral Placebo; Drug
Lead sponsor: Mundipharma Research Limited; Industry
Eligibility: 18 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 13 more

Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: erlotinib, onartuzumab, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 15
States / cities: Bakersfield, California • Fullerton, California • Long Beach, California + 11 more

Search by objective public record fields.

Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects

Oxytocin and Brain Responses in Maternal Addiction

Droxidopa / Pyridostigmine in Orthostatic Hypotension

Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy

A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

CPL-01 in the Management of Postoperative Pain After Bunionectomy

A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

Cryoanalgesia to Treat Post-Amputation Phantom Limb Pain: A Department of Defense Funded Multicenter Study

Effect of Ghrelin on Glucose Metabolism After Bariatric Surgery

SAD and MAD Study of FTX-101 in Healthy Male Subjects

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Participants

Mindfulness Intervention and Symptom Variability in Hearing

Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation